A Prospective, Multicenter, Observational Clinical Study of the Pharmacokinetics and Pharmacodynamics of Venetoclax in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200061294

Enrollment

Unknown

Registered

2022-06-19

Start date

2022-06-06

Completion date

Unknown

Last updated

2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myelodysplastic syndromes, acute myeloid leukemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. AML and MDS diagnosed according to WHO standards; 2. Patients with target indications who agree to use venetoclax for treatment; 3. Can take medicine orally. Able and willing to sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Any active malignancy, except focal non-metastatic squamous cell or basal cell skin cancer or carcinoma in situ; patients with a history of malignancy but cured (eg, no evidence of malignancy for at least 2 years) can join the group; 2. Patients who are known to be allergic to venetoclax.

Design outcomes

Primary

Measure	Time frame
Pharmacokinetics of venetoclax;	—

Countries

China

Contacts

Public ContactHongyan Tong

The First Affiliated Hospital of Zhejiang University Medical College

hongyantong@aliyun.com+86 13958122357

Outcome results